drugset / Trial / NCT05798663
Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC
Phase 2
Active not recruiting
178 enrolled
Alliance Foundation Trials, LLC.
Genentech, Inc. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a phase II trial of neoadjuvant and adjuvant atezolizumab with or without tiragolumab in conjunction with chemoradiotherapy for unresectable stage III NSCLC.
Timeline
- Start
- 2023-12-07
- Primary completion
- 2027-02
- Completion
- 2027-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Atezolizumab | Monoclonal antibody | 1875 mg | Intravenous |
| Subject | Tiragolumab | Monoclonal antibody | 600 mg | Intravenous |